<DOC>
	<DOCNO>NCT01960855</DOCNO>
	<brief_summary>This multi center , randomize , double-blind , placebo-controlled phase 2 study subject moderately severely active rheumatoid arthritis background methotrexate fail anti-Tumor Necrosis Factor ( TNF ) biologic therapy .</brief_summary>
	<brief_title>A Study Investigating Efficacy Safety ABT-494 Given With Methotrexate Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor ( TNF ) Biologic Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Diagnosed RA base either 1987revised American College Rheumatology ( ACR ) classification criterion 2010 American College Rheumatology/European League Rheumatism ( ACR/EULAR ) criteria ≥ 3 month . Subjects must receive oral parenteral MTX therapy ≥ 3 month stable prescription 7.5 25 mg/week least 4 week prior initiate study drug . Subjects also stable dose folic acid ( equivalent ) least 4 week prior initiate study drug . Subjects continue stable dos MTX folic acid throughout study Subjects treat 1 antiTNF biologics ( maximum cap ) ≥ 3 month continue exhibit active RA , discontinue due intolerability toxicity . In addition , subject prior exposure nonantiTNF biologic ( ) ( maximum cap ) ( e.g. , abatacept , rituximab , anakinra , tocilizumab ) allow . Have active RA define follow minimum disease activity criterion : &gt; = 6 swollen joint ( base 66 joint count ) Screening Baseline , &gt; = 6 tender joint ( base 68 joint count ) Screening Baseline , hsCRP &gt; Upper Limit Normal ( ULN ) OR positive rheumatoid factor antiCCP antibody . Prior exposure Janus Activated Kinase ( JAK ) inhibitor ( e.g . tofacitinib , baricitinib ) Pregnant breastfeed female Ongoing active infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>anti-inflammatory agent</keyword>
	<keyword>Joint Diseases</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Musculoskeletal Disease</keyword>
	<keyword>antirheumatic agent</keyword>
</DOC>